Etamsylate versus placebo to prevent bleeding after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3, randomized, double‑blind, placebo‑controlled trial compares etamsylate to placebo in adults who develop thrombocytopenia after hematopoietic stem cell transplantation. Eligible participants are 18–70 years old with platelet counts ≤10×10^9/L persisting for at least five days and adequate organ and coagulation function. The primary endpoint is the incidence of death or WHO grade ≥2 bleeding within 30 days, with secondary endpoints focused on safety and adverse events. The trial is conducted at The First Affiliated Hospital, College of Medicine, Zhejiang University in Hangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 70 years (inclusive), regardless of gender;
2. Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
3. Expected platelet count ≤ 10 x 10⁹/L persisting for 5 days or more;
4. Normal coagulation function;
5. Adequate organ function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the Upper Limit of Normal (ULN), Total Bilirubin ≤ 2 x ULN; Serum Creatinine ≤ 2 x ULN; Creatinine Clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by Echocardiography (ECHO);
6. Voluntary provision of signed informed consent, with the ability to understand and comply with all study requirements.

Exclusion Criteria:

1. Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;
2. Pregnant or breastfeeding women, and women of childbearing potential unwilling to use effective contraception;
3. Presence of active bleeding or infection;
4. History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;
5. Patients with known hereditary or acquired hemorrhagic disorders;
6. Patients receiving anticoagulant or antiplatelet therapy;
7. Patients with severe cardiac insufficiency (left ventricular ejection fraction \[EF\] \< 60%); or severe arrhythmias: history of clinically significant QTc prolongation (male \> 450 ms; female \> 470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block; myocardial infarction within 1 year prior to enrollment; or symptomatic coronary artery disease requiring medication; patients with severe liver impairment (liver function indices \[ALT, TBIL\] \> 3 times the upper limit of normal \[ULN\]);
8. Patients with severe pulmonary insufficiency (obstructive and/or restrictive ventilatory defects);
9. Patients with severe renal insufficiency (renal function index \[Cr\] \> 2 times ULN); or 24-hour urinary creatinine clearance rate (Ccr) \< 50 ml/min;
10. Patients with mental disorders or other conditions preventing provision of informed consent and compliance with study treatment and procedural requirements;
11. Other reasons deemed by the investigator to make the patient ineligible for inclusion.

Where it's running

• The First Affiliated Hospital, College of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Yi Luo — The First Affiliated Hospital, College of Medicine, Zhejiang University Principal Investigator
• Study coordinator: Yi Luo
• Email: luoyijr@zju.edu.com
• Phone: 86-13666609126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

• Population PK-guided ATG Dosing in Haplo-HSCT

  This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07791576

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Personalized ATG dosing in unrelated donor stem cell transplants

  This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07648992

• Estimating Platelet Counts with ROTEM PLTEM in Laboring Women with Low Platelets or Heavy Bleeding

  This study tests whether the PLTEM value from ROTEM sigma testing can quickly estimate platelet count in pregnant women with low platelets or severe postpartum hemorrhage to help decisions about anesthesia and transfusions.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid · NCT07616349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.